Johnson & Johnson Halts Tylenol Production in South Korea Over Mishap

Published: May 06, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Johnson & Johnson may have a new image campaign to help consumers, investors and physicians overlook the cascade of recalls and scandals (see this), but such promotional efforts are no substitute for improved manufacturing procedures. And such gaffes are still occurring. The latest is taking place in South Korea, where its Janssen unit was ordered to halt production of two types of Children's Tylenol syrup because the drugmaker violated manufacturing regulations, The Korea Times writes. The move comes one week after J&J (JNJ) recalled all 170 batches of cherry-flavored Children’s Dye-Free Tylenol Suspension because some bottles contained a higher concentration of the active ingredient - acetaminophen - than specified on the label and could, potentially, cause liver damage. And the drugmaker faces up to six months of production suspension for violating rules, according to the Ministry of Food and Drug Safety.

Help employers find you! Check out all the jobs and post your resume.

Back to news